Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR response and AIP/miR-34a expression study in acromegaly
RBR-29grfmPhase 2Not yet recruiting
- Sponsor
- Federal University of Rio de Janeiro
- Start
- Jun 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in acromegaly, sponsored by Federal University of Rio de Janeiro. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on RBR-29grfm.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-29grfm.